A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

OBJECTIVES: Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS). Azacitidine, first-line treatment for the majority of patients with higher-risk MDS, is associated with aggravated thrombocytopenia during the first cycles. Eltrombopag is a nov...

Bibliografske podrobnosti
Main Authors:	Svensson, T, Chowdhury, O, Garelius, H, Lorenz, F, Saft, L, Jacobsen, SE, Hellström-Lindberg, E, Cherif, H
Format:	Journal article
Jezik:	English
Izdano:	2014

Podobne knjige/članki

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
od: Francesco D’Alò, et al.
Izdano: (2021-04-01)

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
od: Sternberg, A, et al.
Izdano: (2022)

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
od: Dickinson, M, et al.
Izdano: (2018)

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
od: Pedro Marques Ramos, et al.
Izdano: (2023-08-01)

Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
od: Toro Vélez, Esteban, et al.
Izdano: (2021-07-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
od: VM Sthel, et al.
Izdano: (2023-10-01)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
od: Xuan Cai, et al.
Izdano: (2022-10-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
od: KS G&ouml;tze, et al.
Izdano: (2009-10-01)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
od: Unnikrishnan, A, et al.
Izdano: (2017)

Myelodysplastic syndromes
od: Eva Hellström Lindberg
Izdano: (2018-06-01)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
od: Kazuya Sato, et al.
Izdano: (2021-01-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
od: Myrna Candelaria-Hernández, et al.
Izdano: (2017-06-01)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
od: Kathy M. Nilles, et al.
Izdano: (2019-11-01)

Thrombopoietin receptor agonists: ten years later
od: Waleed Ghanima, et al.
Izdano: (2019-06-01)

Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia
od: Michael Makris
Izdano: (2020-03-01)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
od: Kensaku Nakai, et al.
Izdano: (2022-02-01)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
od: Kamel Laribi, et al.
Izdano: (2019-05-01)

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin
od: Yahan Li, et al.
Izdano: (2024-04-01)

Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia
od: Jundong Zhang, et al.
Izdano: (2023-04-01)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
od: Konstantinos Liapis, et al.
Izdano: (2021-02-01)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
od: Ritchie EK
Izdano: (2012-06-01)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine
od: Shinichi Ogawa, et al.
Izdano: (2024-01-01)

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
od: Lars Möllgård, et al.
Izdano: (2011-07-01)

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
od: Olga S. Levchenkova, et al.
Izdano: (2023-03-01)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
od: Hanny Al-Samkari, et al.
Izdano: (2019-04-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
od: Angelica Maria Garzon, et al.
Izdano: (2015-08-01)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
od: Qiuhua Zhu, et al.
Izdano: (2021-08-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
od: Garcia-Manero, G, et al.
Izdano: (2021)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
od: Eri Takada, et al.
Izdano: (2024-02-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
od: I. Mandac Smoljanovic, et al.
Izdano: (2024-01-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
od: Kelly Ann Hutchinson, et al.
Izdano: (2023-05-01)

Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
od: Ai Yoshioka, et al.
Izdano: (2017-11-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
od: Paschalis Evangelidis, et al.
Izdano: (2025-01-01)

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
od: S. G. Zakharov, et al.
Izdano: (2024-04-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
od: A. G. Solodovnikov, et al.
Izdano: (2020-12-01)

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis
od: Rong Hu, et al.
Izdano: (2024-01-01)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
od: Jiwon Shin, et al.
Izdano: (2023-05-01)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
od: Fanqiao Meng, et al.
Izdano: (2020-11-01)

Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic Syndrome
od: Mengying Zhang, et al.
Izdano: (2023-09-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
od: Xin Wang, et al.
Izdano: (2024-12-01)